Marisa W. Friederich

Marisa W. Friederich

Auto-generated profile, based on publicly available information

Marisa W. Friederich

Department of Pediatrics, Section of Clinical Genetics and Metabolism, University of Colorado, Aurora, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2017 in Molecular Genetics and Metabolism
Verified
Journal Article
Open access
EVElise Vantroys
Elise Vantroys
ALAustin Larson
Austin Larson
MFMarisa Friederich
Marisa Friederich
KKKaz Knight
Kaz Knight
MSMichael A. Swanson
Michael A. Swanson
RCRudy Van Coster
Rudy Van Coster
Mutations in FARS2 are known to cause dysfunction of mitochondrial translation due to deficient aminoacylation of the mitochondrial phenylalanine tRNA. Here, we report three novel mutations in FARS2 found in two patients in a compound heterozygous state. The missense mutation c.1082C>T (p.Pro361Leu) was detected in both patients. The mutations c.461C>T (p.Ala154Val) and c.521_523delTGG (p.Val174del) were each detected in one patient. We report abnormal in vitro aminoacylation assays as a functional validation of the molecular genetic findings. Based on the phenotypic data of previously reported subjects and the two subjects reported here, we conclude that FARS2 deficiency can be associated with two phenotypes: (i) an epileptic phenotype, and (ii) a spastic paraplegia phenotype.

1 January 2024
Verified
Journal Article
Open access
JHJohan L. K. Van Hove
Johan L. K. Van Hove
MFMarisa W. Friederich
Marisa W. Friederich
DSDana K. Strode
Dana K. Strode
RHRoxanne A. Van Hove
Roxanne A. Van Hove
KMKristen R. Miller
Kristen R. Miller
RSRonald J. Sokol
Ronald J. Sokol
Background: Mitochondrial hepatopathies (MHs) are primary mitochondrial genetic disorders that can present as childhood liver disease. No recognized biomarkers discriminate MH from other childhood liver diseases. The protein biomarkers growth differentiation factor 15 (GDF15) and fibroblast growth factor 21 (FGF21) differentiate mitochondrial myopathies from other myopathies. We evaluated these biomarkers to determine if they discriminate MH from other liver diseases in children.Methods: Serum biomarkers were measured in 36 children with MH (17 had a genetic diagnosis); 38 each with biliary atresia, alpha 1-antitrypsin deficiency, and Alagille syndrome; 20 with NASH; and 186 controls.Results: GDF15 levels compared to controls were mildly elevated in patients with alpha 1-antitrypsin deficiency, Alagille syndrome, and biliary atresia-young subgroup, but markedly elevated in MH (p<0.001). FGF21 levels were mildly elevated in NASH and markedly elevated in MH (p98th percentile of controls identified genetically confirmed MH with a sensitivity of 88% and specificity of 96%. In MH, independent predictors of survival without requiring liver transplantation were international normalized ratio and either GDF15 or FGF21 levels, with levels <2000 ng/L predicting survival without liver transplantation (p<0.01).Conclusions: GDF15 and FGF21 are significantly higher in children with MH compared to other childhood liver diseases and controls and, when combined, were predictive of MH and had prognostic implications.

5 June 2024 in Journal of Inherited Metabolic Disease
Verified
Journal Article
Closed access
MSMichael A. Swanson
Michael A. Swanson
HJHua Jiang
Hua Jiang
NBNicolas Busquet
Nicolas Busquet
JCJessica Carlsen
Jessica Carlsen
CBConnie Brindley
Connie Brindley
JHJohan L. K. Van Hove
Johan L. K. Van Hove

7 October 2025 in Molecular Genetics and Metabolism
Verified
Journal Article
Closed access
MFMarisa W. Friederich
Marisa W. Friederich
JHJohan L.K. Van Hove
Johan L.K. Van Hove

8 September 2026 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
JHJohan L K Van Hove
Johan L K Van Hove
MFMarisa W Friederich
Marisa W Friederich
RHRoxanne A Van Hove
Roxanne A Van Hove
JLJessica C Lee
Jessica C Lee
KKKaz M Knight
Kaz M Knight
JYJennifer H Yang
Jennifer H Yang
Genome sequencing is the first-line diagnostic method for primary mitochondrial diseases (PMDs), yet its effectiveness is limited by variants of uncertain significance or unresolved genetic findings. We systematically evaluated the clinical performance of fibroblast-based functional testing, comprised of respiratory chain enzyme assays, blue native polyacrylamide gel electrophoresis with in-gel activity staining (BN-PAGE), complex I assembly assay, and targeted protein abundance assessments, in a cohort of 204 genetically confirmed PMD patients, 51 healthy controls, and 53 patients with differential diagnoses. Individually, enzyme assays, BN-PAGE, and complex I assembly assay showed sensitivities of 46%, 40%, and 49%, with specificities of 93%, 98%, and 99%, respectively. Combined, the assays achieved an overall sensitivity of 76%, a specificity 93%, a positive predictive value 96%, and a negative predictive value of 67%. Sensitivity was highest for isolated respiratory chain deficiencies, nuclear DNA-encoded mitochondrial translation defects, cofactor deficiencies, and mitochondrial aminoacyl-tRNA synthetase disorders, whereas mitochondrial DNA variants and maintenance defects remained challenging. Secondary mitochondrial dysfunction was rare. The strong clinical utility of comprehensive fibroblast functional testing improves PMD diagnosis when used complementary to genomic sequencing.